Lunai Bioworks Inc. develops AI-enabled life sciences platforms for drug discovery, precision therapeutics and chemical defense applications. Company news centers on the Augusta platform, BioSymetrics' phenotypic screening and machine-learning capabilities, and programs tied to central nervous system diseases, oncology and biodefense.
Recurring updates include intellectual property additions, patent issuances, commercial collaborations, defense-focused chemical threat assessment work, and capital transactions used to support platform expansion. Recent company developments also cover CNS delivery technologies, neurotherapeutic patent assets, patient-stratification methods, and the integration of clinical, genomic and phenotypic data into drug discovery workflows.
Lunai Bioworks (LNAI) entered an exclusive worldwide license and collaboration agreement with Tanaist to add human cellular phenotyping to its AI-driven Parkinson's disease discovery and validation platform.
The deal grants Lunai exclusive rights to Tanaist's licensed cellular phenotyping technology in the Parkinson's field for programs based on Lunai's patient phenoclusters. The partners will test whether Lunai's clinical and proteomic signatures, including previously defined patient subtypes, can be reproduced across agreed Parkinson's cohorts and linked to measurable differences in human cellular biology, supporting biomarker and therapeutic target development. Lunai will own collaboration-generated analyses, biomarker findings and related intellectual property, while Tanaist retains ownership of its underlying platform.
Lunai Bioworks (LNAI) reported a BioSymetrics case study showing AI-based screening of chemical structures for acetylcholinesterase (AChE) inhibition, aimed at supporting chemical-risk controls for generative AI outputs.
Using NIH Tox21 AChE assay data on 9,667 compounds, the selected model achieved an AUROC of 0.88 and 33% precision at 70% recall, corresponding to about 5.1-fold enrichment over the dataset’s 6.4% prevalence of AChE‑active entries. The structure-based screen is designed to operate independently of any specific large language model or molecular-generation system and to act as a downstream layer that prioritizes molecules for further computational, expert, or biological review.
The work extends a multi-year, revenue-generating defense collaboration that links mechanism-of-action modeling with in vivo zebrafish phenotypic screening, and underpins more than US$30 million in submitted, but not yet awarded, non-dilutive grant applications in chemical defense and biosecurity.
Lunai Bioworks (LNAI) issued a correction on September 4, 2026 to its August 27, 2026 press release related to a Second Amended Complaint.
The only change is an updated hyperlink specifying where the Second Amended Complaint is available. All other statements in the original release remain accurate and unchanged, and no new information is being disclosed. The complaint can now be accessed via Lunai Bioworks’ investor relations website or directly through the court’s public docket.
Summary not available.
Lunai Bioworks (Nasdaq: LNAI) signed a Master Collaboration Agreement with BrainStorm Therapeutics to integrate BioSymetrics' Contingent AI™ patient-stratification platform with BrainStorm's familial Parkinson's disease midbrain organoid and AI platform. The companies are targeting an initial Parkinson's disease data readout in the first half of 2027.
According to Lunai, the collaboration will align clinically defined Parkinson's disease subtypes with biological mechanisms, prioritize biomarkers and targets, test disease hypotheses in patient-derived midbrain organoids and in vivo systems, and develop partner-ready decision packages for pharmaceutical and biotechnology collaborators, supported by a new BioSymetrics white paper on Parkinson's subtypes.
Summary not available.
Lunai Bioworks (NASDAQ:LNAI) CEO outlined progress in biodefense, precision neurology, and shareholder protections. The company secured its first revenue-generating, multi-year U.S. defense contract via BioSymetrics for AI-enabled chemical threat assessment and formed the Pathfinder Consortium with leading universities.
Lunai is advancing its Augusta™ AI neurology platform in epilepsy, Parkinson’s, and Alzheimer’s, including a BrainStorm collaboration and a Phase I/II NIH STTR grant of $1.85 million. The company initiated litigation over alleged naked short selling, is in expedited discovery, and reports renewed compliance with NASDAQ listing requirements.
Lunai Bioworks (NASDAQ:LNAI), via subsidiary BioSymetrics, and BrainStorm Therapeutics announced a foundation-funded neurology discovery collaboration. The partnership integrates AI target discovery, human brain organoids, and in vivo zebrafish models to identify and validate therapeutic targets for Parkinson's disease, rare genetic epilepsies, and other neurodegenerative disorders.
Backed by a LouLou Foundation grant and a Letter of Intent to broaden indications, the collaboration aims to create a portfolio of biologically validated, development-ready neurology programs for pharmaceutical partnering, licensing, and other non-dilutive funding structures.
Summary not available.
Lunai Bioworks (Nasdaq:LNAI) will implement a 1-for-8 reverse stock split of its common stock, effective 12:01 a.m. ET on May 22, 2026. Shares will begin trading on a split-adjusted basis that day under LNAI with new CUSIP 29350E302.
The split, approved by stockholders and set by the board, is intended to increase the per-share price to help regain compliance with Nasdaq Listing Rule 5550(a)(2). Outstanding shares will decline from about 36.27 million to about 4.53 million, with no change to par value or authorized shares, and fractional shares rounded up.